CD8A and colorectal cancer: Cao et al. (2024) constructed a PLGA-based nanovaccine (NP-TCL@APS), co-loaded with APS and tumor cell lysates, which not only facilitated antigen delivery but also effectively activated CD8+ T-cell-mediated immune responses, showing promising therapeutic potential against colorectal cancer.